Risk Factors for Poor Response to Denosumab Treatment in Japanese Postmenopausal Women with Osteoporosis

Overview

Journal J Bone Miner Metab

Specialty Endocrinology

Date 2022 Aug 8

PMID 35939236

Authors

Tokutaro Okawa

Motomi Okawa

Tatsuya Koike

Affiliations

Soon will be listed here.

Abstract

Introduction: Denosumab has been reported to increase bone mineral density (BMD) and suppress fractures, but poor responders are not uncommon. This study aimed to identify risk factors for poor response to denosumab treatment. This is the first study to explore risk factors for poor response to denosumab.

Materials And Methods: This retrospective observational study investigated 227 Japanese postmenopausal women who received denosumab with monitoring of BMD by dual-energy X-ray absorptiometry at 6-month intervals. Risk factors were identified using Cox's proportional hazard modeling. Poor responders were defined as not exceeding the least significant change of BMD from baseline for 3 years.

Results: Mean relative change from baseline for 3 years in lumbar spine (LS)-BMD, femoral neck (FN)-BMD, and total hip (TH)-BMD were 12.6%, 6.8%, and 6.1%, respectively. Numbers of poor responders were 10 in LS-BMD, 47 in FN-BMD, 38 in TH-BMD. Risk factors for poor response were concomitant glucocorticoid use for LS-BMD, low body mass index or initiation at higher BMD for FN-BMD, and pretreatment with bisphosphonates or initiation at higher BMD for TH-BMD.

Conclusion: Risk factors for insufficient denosumab effect differed between BMD measurement sites. These results should be taken into consideration when selecting denosumab in clinical practice.

Citing Articles

Risk factors for nonresponse to 2 years of denosumab administration in patients with osteoporosis: A retrospective single-center cohorts study.

Yamamoto A, Nagao M, Nishizaki Y, Maeda E, Ishijima M Health Sci Rep. 2024; 7(4):e1993.

PMID: 38585014 PMC: 10995440. DOI: 10.1002/hsr2.1993.

Zinc improves Denosumab and eldecalcitol efficacy for bone mineral density in patients with hypozincemia.

Ishizu H, Shimizu T, Ohashi Y, Kusunoki K, Kanayama M, Iwasaki N J Bone Miner Metab. 2024; 42(2):233-241.

PMID: 38324176 DOI: 10.1007/s00774-024-01498-3.

References

McCombs J, Thiebaud P, McLaughlin-Miley C, Shi J . Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004; 48(3):271-87. DOI: 10.1016/j.maturitas.2004.02.005. View

Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate J . Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2009; 21(11):1943-51. DOI: 10.1007/s00198-009-1134-4. View

Sampalis J, Adachi J, Rampakakis E, Vaillancourt J, Karellis A, Kindundu C . Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Miner Res. 2011; 27(1):202-10. DOI: 10.1002/jbmr.533. View

McClung M, Lewiecki E, Cohen S, Bolognese M, Woodson G, Moffett A . Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006; 354(8):821-31. DOI: 10.1056/NEJMoa044459. View

Kamimura M, Nakamura Y, Ikegami S, Uchiyama S, Kato H, Taguchi A . Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients. Osteoporos Int. 2016; 28(2):559-566. PMC: 5269470. DOI: 10.1007/s00198-016-3764-7. View

Kendler D, Roux C, Benhamou C, Brown J, Lillestol M, Siddhanti S . Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2009; 25(1):72-81. DOI: 10.1359/jbmr.090716. View

Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I . Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014; 99(7):2599-607. PMC: 4191553. DOI: 10.1210/jc.2013-4175. View

Lewiecki E . Denosumab in postmenopausal osteoporosis: what the clinician needs to know. Ther Adv Musculoskelet Dis. 2012; 1(1):13-26. PMC: 3382669. DOI: 10.1177/1759720X09343221. View

Moen M, Keam S . Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2010; 28(1):63-82. DOI: 10.2165/11203300-000000000-00000. View

10.

Jamal S, Ljunggren O, Stehman-Breen C, Cummings S, McClung M, Goemaere S . Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011; 26(8):1829-35. DOI: 10.1002/jbmr.403. View

11.

Lipton A, Fizazi K, Stopeck A, Henry D, Brown J, Yardley D . Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012; 48(16):3082-92. DOI: 10.1016/j.ejca.2012.08.002. View

12.

McClung M, Lewiecki E, Geller M, Bolognese M, Peacock M, Weinstein R . Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2012; 24(1):227-35. PMC: 3536967. DOI: 10.1007/s00198-012-2052-4. View

13.

Jones A, Sim I . Denosumab failure associated with escape from suppression of bone resorption. Bone. 2019; 131:115157. DOI: 10.1016/j.bone.2019.115157. View

14.

Baim S, Wilson C, Lewiecki E, Luckey M, Downs Jr R, Lentle B . Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom. 2005; 8(4):371-8. DOI: 10.1385/jcd:8:4:371. View

15.

Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N . Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab. 2013; 31(3):247-57. DOI: 10.1007/s00774-013-0447-8. View

16.

Lodder M, Lems W, Ader H, Marthinsen A, van Coeverden S, Lips P . Reproducibility of bone mineral density measurement in daily practice. Ann Rheum Dis. 2004; 63(3):285-9. PMC: 1754906. DOI: 10.1136/ard.2002.005678. View

17.

Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K . Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. J Bone Miner Metab. 2004; 22(5):462-8. DOI: 10.1007/s00774-004-0508-0. View

18.

Soen S, Arai Y, Matsuda S, Emori K, Ikezaki T, Osawa M . A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis. Osteoporos Sarcopenia. 2021; 6(4):191-198. PMC: 7783076. DOI: 10.1016/j.afos.2020.11.002. View

19.

Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y . Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab. 2011; 30(4):439-46. PMC: 3396350. DOI: 10.1007/s00774-011-0332-2. View

20.

Suzuki T, Nakamura Y, Kato H . Efficacy, safety, and compliance of ibandronate treatment for 3 years in postmenopausal Japanese women with primary osteoporosis. Osteoporos Sarcopenia. 2019; 4(2):69-72. PMC: 6362971. DOI: 10.1016/j.afos.2018.04.001. View